Piramal Pharma Solutions Augments Integrated Capabilities by Expanding Sterile Manufacturing Capabilities in Lexington KY

Thursday, March 23, 2017

Piramal Pharma Solutions PPS a leading Contract Development and Manufacturing Organization CDMO held a special event to introduce the new and expanded manufacturing capabilities at its facilities in Lexington Kentucky The inaugural event was attended by Governor Matt Bevin Piramal Group Chairman Aja..

Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 SHP655 for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura

Thursday, March 23, 2017

Shire plc today announced that the United States Food and Drug Administration FDA has granted Fast Track designation for recombinant ADAMTS13 SHP655 historically known as BAX930 for treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura hTTP in patients with a constitutional ..

XChem and Ono Enter into MultiTarget Drug Discovery Collaboration

Wednesday, March 22, 2017

XChem Inc a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics today announced a partnership with Ono Pharmaceutical Co Ltd Ono Under the terms of the agreement XChem will apply its proprietary DEXTM libraries w..

MilliporeSigma Introduces Mobius MyWay Portfolio for Customized Singleuse Assemblies

Wednesday, March 22, 2017

MilliporeSigma a leader in singleuse technology today launched an industry firstthe Mobius MyWay portfolio a program that allows more flexibility better supply predictability and shorter lead times for more efficient and safer drug manufacture We have the industry39s only comprehensive singleuse ..

Ferring and CDI sign agreement granting Ferring exclusive marketing rights to VSL3 in Europe and Canada

Tuesday, March 21, 2017

Ferring Pharmaceuticals and CD Investments CDI announced today that they have signed an agreement granting Ferring exclusive European marketing rights to CDIs VSL3 This agreement extends Ferrings existing rights to market the product in the UK Italy and Canada VSL3 is a food supplement containing..

Cerulean Pharma and Dar Bioscience Enter into Stock Purchase Agreement

Tuesday, March 21, 2017

Cerulean Pharma Inc and Dar Bioscience Inc a privatelyheld clinicalstage pharmaceutical company advancing products for womens reproductive health today announced that the two companies together with the equityholders of Dar Bioscience have entered into a definitive stock purchase agreement under whi..

Turkish Cargo is the Fastest Growing International Cargo Airline of the Year

Tuesday, March 21, 2017

Turkish Cargo was awarded the 3939Fastest Growing International Cargo Airline of the Year3939 award at the Air Cargo Africa 2017 fair A total of 3000 participants from 61 countries and a large number of companies operating in theAfrican aircargo market participated in the 4th Air Cargo Africa fai..

Government Aims to Make India a Global Biotech Hub by 2020

Monday, March 20, 2017
Bussinesswireind

Business Wire IndiaThe Biotechnology Industry Research Assistance Council BIRAC celebrated its 5th Foundation Day on Monday in New Delhi The 5th Foundation Day aptly themed Impacting the Biotech Innovation Ecosystem was presided over by the Minister of State for Science and Technology Earth Science..

Valeant Announces the Early Results of Tender Offers for Its 675 Senior Notes Due 2018

Monday, March 20, 2017
PR Newswire

LAVAL Quebec March 20 2017 PRNewswire Valeant Pharmaceuticals International Inc NYSE VRX TSX VRX Valeant or the Company announced today that as of 500 pm New York City time on March 20 2017 the Early Participation Date holders of its outstanding 675 Senior Notes due 2018 the Notes had validly tend..

Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients

Monday, March 20, 2017

Amgen today announced new data from two studies that showed that for appropriate patients onlabel in the US the majority of prescription claims for PCSK9 inhibitors such as Repatha evolocumab were initially rejected Additionally one of the studies showed no major differences in patient characteristi..

Surefire Receives Regulatory Approval for Infusion Systems and Guiding Catheters in Mexico

Monday, March 20, 2017
GLOBE NEWSWIRE

WESTMINSTER Colo March 20 2017 GLOBE NEWSWIRE Surefire Medical Inc the developer of sitespecific delivery devices for the Interventional Oncology market announced today that the company has received regulatory approval in Mexico for its Surefire Infusion Systems and Surefire Guiding Catheters ..

Amydis Diagnostics Awarded NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimers Disease

Monday, March 20, 2017
GLOBE NEWSWIRE

SAN DIEGO March 20 2017 GLOBE NEWSWIRE Amydis Diagnostics Inc a preclinical stage privatelyheld pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloidrelated neurodegenerative disorders such as Alzheimers disease announced that they received..

Cytokinetics Announces Additional Results From COSMICHF Presented at ACC17

Monday, March 20, 2017
GLOBE NEWSWIRE

SOUTH SAN FRANCISCO Calif March 20 2017 GLOBE NEWSWIRE Cytokinetics Inc NasdaqCYTK today announced that additional results from COSMICHF Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic hea..

Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO202 for the Reduction of Submental Subcutaneous Fat

Monday, March 20, 2017
GLOBE NEWSWIRE

SAN DIEGO March 20 2017 GLOBE NEWSWIRE Neothetics Inc NASDAQNEOT a clinicalstage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced completion of subject enrollment for its Phase 2 proof of concept trial LIPO202CL31 for the reduction of submental ..

Weve Proven It Works dHydronator the Worlds Only Consumer Cannabis Dryer Sanitizer Testing Results and Plans Moving Forward for THC Therapeutics Comments from CEO

Monday, March 20, 2017
GLOBE NEWSWIRE

LAS VEGAS March 20 2017 GLOBE NEWSWIRE THC Therapeutics Inc THCT A publicly traded health and healing cannabis companyOver the past two years we have created two generations of the dHydronator with builtin SanitiZen technology which have been subjected to rigorous independent laboratory testin..

BeyondSpring Lead Asset Plinabulins AntiCancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British Columbia

Monday, March 20, 2017
GLOBE NEWSWIRE

NEW YORK March 20 2017 GLOBE NEWSWIRE BeyondSpring Inc NASDAQBYSI a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies today announced that an abstract on the molecular action describing the immunological involvement in the anticancer effe..

Sharecare Named a TAG Top 10 Innovative Technology Company

Monday, March 20, 2017
GLOBE NEWSWIRE

ATLANTA March 20 2017 GLOBE NEWSWIRE The Technology Association of Georgia TAG the states leading association dedicated to the promotion and economic advancement of Georgias technology industry today announced Sharecare as one of its Top 10 Innovative Technology Companies in Georgia TAG will r..

Rocky Mountain High BrandsAnnounces Retirement of Shares

Monday, March 20, 2017
GLOBE NEWSWIRE

DALLAS March 20 2017 GLOBE NEWSWIRE Rocky Mountain High Brands Inc OTCQBRMHB a fully reporting consumer goods company specializing in hempinfused food and beverage products and a naturally high alkaline water announced today that the Officers and Directors are voluntarily returning 25000000 shar..

Aralez CEO Purchases 500000 Shares Of Company Common Stock On Open Market

Monday, March 20, 2017
PR Newswire

MISSISSAUGA Ontario March 20 2017 PRNewswire Aralez Pharmaceuticals Inc NASDAQ ARLZ TSX ARZ Aralez or the Companytoday announced that Adrian Adams the Chief Executive Officer of the Company acquired an additional 500000 shares of the Companys common stock on March 15 2017 in openmarket purchases ..

Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of ProgressionFree Survival

Monday, March 20, 2017
PR Newswire

INDIANAPOLIS March 20 2017 PRNewswire Eli Lilly and Company NYSE LLY today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progressionfree survival PFS The Phase 3 study evaluated abemaciclib a cyclindependent kinase CDK 4 and CDK 6 inhibitor in combination with fulve..

TOP